{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T19:21:55Z","timestamp":1784056915330,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"JSPS KAKENHI","award":["JP19K09684"],"award-info":[{"award-number":["JP19K09684"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-13895-6","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T20:12:12Z","timestamp":1742587932000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The combination of poly(ADP-ribose) polymerase inhibitor and statin inhibits the proliferation of human castration-resistant and taxane-resistant prostate cancer cells in vitro and in vivo"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8094-4524","authenticated-orcid":false,"given":"Yoshitaka","family":"Sekine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ohtsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Miyao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Miyazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"issue":"5","key":"13895_CR1","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1405095.","journal-title":"N Engl J Med"},{"issue":"2","key":"13895_CR2","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, Rathkopf DE, Miller K, de Bono JS, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152\u201360. https:\/\/doi.org\/10.1016\/S1470-2045(14)71205-7.","journal-title":"Lancet Oncol"},{"issue":"15","key":"13895_CR3","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","volume":"378","author":"MR Smith","year":"2018","unstructured":"Smith MR, Saad F, Chowdhury S, Fizazi K, Sternberg CN, Cella D, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378(15):1408\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1715546.","journal-title":"N Engl J Med"},{"issue":"13","key":"13895_CR4","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","volume":"380","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380(13):1235\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1815671.","journal-title":"N Engl J Med"},{"key":"13895_CR5","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ejca.2019.01.008","volume":"112","author":"MI Van Rompay","year":"2019","unstructured":"Van Rompay MI, Solomon KR, Nickel JC, Ranganathan G, Kantoff PW, McKinlay JB. Prostate cancer incidence and mortality among men using Statins and non-statin lipid-lowering medications. Eur J Cancer. 2019;112:118\u201326. https:\/\/doi.org\/10.1016\/j.ejca.2019.01.008.","journal-title":"Eur J Cancer"},{"issue":"2","key":"13895_CR6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/pcan.2016.1","volume":"19","author":"AD Raval","year":"2016","unstructured":"Raval AD, Thakker D, Negi H, Vyas A, Kaur H, Salkini MW. Association between Statins and clinical outcomes among men with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2016;19(2):151\u201362. https:\/\/doi.org\/10.1038\/pcan.2016.1.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"13895_CR7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.prnil.2016.03.001","volume":"4","author":"Y Furuya","year":"2016","unstructured":"Furuya Y, Sekine Y, Kato H, Miyazawa Y, Koike H, Suzuki K. Low-density lipoprotein receptors play an important role in the Inhibition of prostate cancer cell proliferation by Statins. Prostate Int. 2016;4(2):56\u201360. https:\/\/doi.org\/10.1016\/j.prnil.2016.03.001.","journal-title":"Prostate Int"},{"issue":"4","key":"13895_CR8","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1172\/JCI21404","volume":"115","author":"L Zhuang","year":"2005","unstructured":"Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest. 2005;115(4):959\u201368. https:\/\/doi.org\/10.1172\/JCI21404.","journal-title":"J Clin Invest"},{"issue":"6","key":"13895_CR9","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.ejca.2011.01.018","volume":"47","author":"G Papadopoulos","year":"2011","unstructured":"Papadopoulos G, Delakas D, Nakopoulou L, Kassimatis T. Statins and prostate cancer: molecular and clinical aspects. Eur J Cancer. 2011;47(6):819\u201330. https:\/\/doi.org\/10.1016\/j.ejca.2011.01.018.","journal-title":"Eur J Cancer"},{"issue":"2","key":"13895_CR10","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.bbrc.2008.05.051","volume":"372","author":"Y Sekine","year":"2008","unstructured":"Sekine Y, Furuya Y, Nishii M, Koike H, Matsui H, Suzuki K. Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor. Biochem Biophys Res Commun. 2008;372(2):356\u201361. https:\/\/doi.org\/10.1016\/j.bbrc.2008.05.051.","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"13895_CR11","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1158\/1541-7786.MCR-08-0110","volume":"8","author":"Y Sekine","year":"2008","unstructured":"Sekine Y, Demosky SJ, Stonik JA, Furuya Y, Koike H, Suzuki K. High-density lipoprotein induces proliferation and migration of human prostate androgen-independent cancer cells by an ABCA1-dependent mechanism. Mol Cancer Res. 2008;8(9):1284\u201394. https:\/\/doi.org\/10.1158\/1541-7786.MCR-08-0110.","journal-title":"Mol Cancer Res"},{"issue":"4","key":"13895_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/pros.23267","volume":"77","author":"Y Miyazawa","year":"2017","unstructured":"Miyazawa Y, Sekine Y, Kato H, Furuya Y, Koike H, Suzuki K. Simvastatin up-regulates Annexin A10 that can inhibit the proliferation, migration, and invasion in androgen-independent human prostate cancer cells. Prostate. 2017;77(4):337\u201349. https:\/\/doi.org\/10.1002\/pros.23267.","journal-title":"Prostate"},{"issue":"2","key":"13895_CR13","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ccr.2011.01.010","volume":"19","author":"LW Ellisen","year":"2011","unstructured":"Ellisen LW, Farmer H, McCabe N, Lord CJ, Ashworth A, Yu VP. PARP inhibitors in cancer therapy: promise, progress, and puzzles. Cancer Cell. 2011;19(2):165\u20137. https:\/\/doi.org\/10.1016\/j.ccr.2011.01.010.","journal-title":"Cancer Cell"},{"issue":"7381","key":"13895_CR14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nature10760","volume":"481","author":"CJ Lord","year":"2012","unstructured":"Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature. 2012;481(7381):287\u201394. https:\/\/doi.org\/10.1038\/nature10760.","journal-title":"Nature"},{"issue":"18","key":"13895_CR15","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo J, Carreira S, Sandhu S, de Bono J, Olmos D, Reid AH. DNA-repair defects and Olaparib in metastatic prostate cancer. N Engl J Med. 2015;373(18):1697\u2013708. https:\/\/doi.org\/10.1056\/NEJMoa1506859.","journal-title":"N Engl J Med"},{"issue":"1","key":"13895_CR16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","volume":"21","author":"J Mateo","year":"2020","unstructured":"Mateo J, Porta N, Bianchini D, McGovern UB, Elliott T, Sandhu S. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicenter, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21(1):162\u201374. https:\/\/doi.org\/10.1016\/S1470-2045(19)30684-9.","journal-title":"Lancet Oncol"},{"issue":"480","key":"13895_CR17","doi-asserted-by":"publisher","first-page":"eaam7479","DOI":"10.1126\/scisignal.aam7479","volume":"10","author":"L Li","year":"2017","unstructured":"Li L, Karanika S, Yang G, Wang J, Bajpai R, Magi-Galluzzi C, et al. Androgen receptor inhibitor\u2013induced BRCAness and PARP Inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal. 2017;10(480):eaam7479. https:\/\/doi.org\/10.1126\/scisignal.aam7479.","journal-title":"Sci Signal"},{"issue":"1","key":"13895_CR18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.21873\/anticanres.13181","volume":"44","author":"D Oka","year":"2024","unstructured":"Oka D, Sekine Y, Tsuji Y, Furuya Y, Koike H, Suzuki K. Simvastatin enhances the radiosensitivity of androgen-independent prostate cancer cells via Inhibition of RAD51 expression. Anticancer Res. 2024;44(1):93\u20138. https:\/\/doi.org\/10.21873\/anticanres.13181.","journal-title":"Anticancer Res"},{"issue":"9","key":"13895_CR19","doi-asserted-by":"publisher","first-page":"5091","DOI":"10.21873\/anticanres.14512","volume":"40","author":"T Miyao","year":"2020","unstructured":"Miyao T, Koike H, Sekine Y, Ohtsu A, Oka D, Suzuki K. YM155 reverses Cabazitaxel resistance in Castration-resistant prostate cancer by reducing survivin expression. Anticancer Res. 2020;40(9):5091\u20135. https:\/\/doi.org\/10.21873\/anticanres.14512.","journal-title":"Anticancer Res"},{"issue":"6","key":"13895_CR20","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/ijc.10422","volume":"99","author":"K Suzuki","year":"2002","unstructured":"Suzuki K, Koike H, Matsui H, Sekine Y, Furuya Y, Kato H. Genistein, a soy isoflavone, induces glutathione peroxidase in the human prostate cancer cell lines LNCaP and PC-3. Int J Cancer. 2002;99(6):846\u201352. https:\/\/doi.org\/10.1002\/ijc.10422.","journal-title":"Int J Cancer"},{"issue":"4","key":"13895_CR21","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001;25(4):402\u20138. https:\/\/doi.org\/10.1006\/meth.2001.1262.","journal-title":"Methods"},{"issue":"15","key":"13895_CR22","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or Mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502\u201312. https:\/\/doi.org\/10.1056\/NEJMoa040720.","journal-title":"N Engl J Med"},{"issue":"26","key":"13895_CR23","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","volume":"381","author":"R de Wit","year":"2019","unstructured":"de Wit R, de Bono J, Sternberg CN, Chi KN, Omlin A, Sartor AO, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med. 2019;381(26):2506\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1911206.","journal-title":"N Engl J Med"},{"issue":"4","key":"13895_CR24","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/leu.2010.6","volume":"24","author":"LJ Mah","year":"2010","unstructured":"Mah LJ, El-Osta A, Karagiannis TC. gammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia. 2010;24(4):679\u201386. https:\/\/doi.org\/10.1038\/leu.2010.6.","journal-title":"Leukemia"},{"issue":"3","key":"13895_CR25","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/jcpt.13058","volume":"45","author":"H Yang","year":"2020","unstructured":"Yang H, Pang L, Hu X, Wang S, Li C, Sun H. The effect of Statins on advanced prostate cancer patients with androgen deprivation therapy or Abiraterone\/enzalutamide: A systematic review and meta-analysis. J Clin Pharm Ther. 2020;45(3):488\u201395. https:\/\/doi.org\/10.1111\/jcpt.13058.","journal-title":"J Clin Pharm Ther"},{"issue":"14","key":"13895_CR26","doi-asserted-by":"publisher","first-page":"7797","DOI":"10.1073\/pnas.96.14.7797","volume":"96","author":"S Rao","year":"1996","unstructured":"Rao S, Porter DC, Chen X, Herliczek T, Lowe M, Keyomarsi K. Lovastatin-mediated G1 arrest is through Inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci USA. 1996;96(14):7797\u2013802. https:\/\/doi.org\/10.1073\/pnas.96.14.7797.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"13895_CR27","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/pros.21246","volume":"71","author":"A Yokomizo","year":"2011","unstructured":"Yokomizo A, Shiota M, Kashiwagi E, Kuroiwa K, Naito S, Inoue T. Statins reduce the androgen sensitivity and cell proliferation by decreasing the androgen receptor protein in prostate cancer cells. Prostate. 2011;71(3):298\u2013304. https:\/\/doi.org\/10.1002\/pros.21246.","journal-title":"Prostate"},{"issue":"37","key":"13895_CR28","doi-asserted-by":"publisher","first-page":"14328","DOI":"10.1074\/jbc.RA118.004335","volume":"293","author":"Y Kong","year":"2018","unstructured":"Kong Y, Cheng L, Mao F, Zhang J, Liu F, Song Y. Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC). J Biol Chem. 2018;293(37):14328\u201341. https:\/\/doi.org\/10.1074\/jbc.RA118.004335.","journal-title":"J Biol Chem"},{"issue":"6","key":"13895_CR29","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, Olaparib I, Villanueva-V\u00e1zquez R, Yearley J, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1706450.","journal-title":"N Engl J Med"},{"issue":"9","key":"13895_CR30","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F, Paluch-Shimon S, Cibula D, Colombo N, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274\u201384. https:\/\/doi.org\/10.1016\/S1470-2045(17)30469-2.","journal-title":"Lancet Oncol"},{"issue":"4","key":"13895_CR31","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M, O\u2019Reilly EM, Macarulla T, Mehta A, et al. Maintenance Olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1903387.","journal-title":"N Engl J Med"},{"issue":"7035","key":"13895_CR32","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Knights C, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917\u201321. https:\/\/doi.org\/10.1038\/nature03445.","journal-title":"Nature"},{"issue":"7406","key":"13895_CR33","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nature11125","volume":"487","author":"CS Grasso","year":"2012","unstructured":"Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487(7406):239\u201343. https:\/\/doi.org\/10.1038\/nature11125.","journal-title":"Nature"},{"issue":"1","key":"13895_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","volume":"18","author":"BS Taylor","year":"2010","unstructured":"Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11\u201322. https:\/\/doi.org\/10.1016\/j.ccr.2010.05.026.","journal-title":"Cancer Cell"},{"issue":"7","key":"13895_CR35","first-page":"620","volume":"27","author":"CL Derleth","year":"2013","unstructured":"Derleth CL, Yu EY. Targeted therapy in the treatment of castration-resistant prostate cancer. Oncol (Williston Park). 2013;27(7):620\u20138.","journal-title":"Oncol (Williston Park)"},{"issue":"6","key":"13895_CR36","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1200\/JCO.2011.39.2210","volume":"30","author":"PS Nelson","year":"2012","unstructured":"Nelson PS. Molecular States underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer. J Clin Oncol. 2012;30(6):644\u20136. https:\/\/doi.org\/10.1200\/JCO.2011.39.2210.","journal-title":"J Clin Oncol"},{"issue":"3","key":"13895_CR37","doi-asserted-by":"publisher","first-page":"e627","DOI":"10.1016\/j.clgc.2019.04.007","volume":"17","author":"F Leaf","year":"2019","unstructured":"Leaf F, Garcia-Perdomo HA. Effectiveness of platinum-based chemotherapy in patients with metastatic prostate cancer: systematic review and meta-analysis. Clin Genitourin Cancer. 2019;17(3):e627\u201344. https:\/\/doi.org\/10.1016\/j.clgc.2019.04.007.","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"13895_CR38","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","volume":"20","author":"KP Pennington","year":"2014","unstructured":"Pennington KP, Walsh T, Harrell MI, Rendi MH, Thornton TA, Norquist BM, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764\u201375. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2287.","journal-title":"Clin Cancer Res"},{"issue":"22","key":"13895_CR39","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1158\/0008-5472.CAN-12-0470","volume":"72","author":"A Mukhopadhyay","year":"2012","unstructured":"Mukhopadhyay A, Plummer ER, Elattar A, Sandhu SK, Sundar S, Ganesan TS, et al. Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival. Cancer Res. 2012;72(22):5675\u201382. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-0470.","journal-title":"Cancer Res"},{"issue":"9","key":"13895_CR40","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/pros.20944","volume":"69","author":"TJ Murtola","year":"2009","unstructured":"Murtola TJ, Pennanen P, Syv\u00e4l\u00e4 H, Bl\u00e4uer M, Ylikomi T, Tammela TL. Effects of Simvastatin, acetylsalicylic acid, and Rosiglitazone on proliferation of normal and cancerous prostate epithelial cells at therapeutic concentrations. Prostate. 2009;69(9):1017\u201323. https:\/\/doi.org\/10.1002\/pros.20944.","journal-title":"Prostate"},{"issue":"3","key":"13895_CR41","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1124\/jpet.105.094136","volume":"316","author":"KM Thelen","year":"2006","unstructured":"Thelen KM, Rentsch KM, Gutteck U, Heverin M, Olin H, Andersson U, et al. Brain cholesterol synthesis in mice is affected by high dose of Simvastatin but not of Pravastatin. J Pharmacol Exp Ther. 2006;316(3):1146\u201352. https:\/\/doi.org\/10.1124\/jpet.105.094136.","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"13895_CR42","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1158\/1535-7163.MCT-11-0278","volume":"10","author":"JM Senra","year":"2011","unstructured":"Senra JM, Telfer BA, Cherry KE, McCrudden CM, Hirst DG, O`Connor MJ, et al. Inhibition of PARP-1 by Olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. Mol Cancer Ther. 2011;10(10):1949\u201358. https:\/\/doi.org\/10.1158\/1535-7163.MCT-11-0278.","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"13895_CR43","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.3390\/cancers11091373","volume":"11","author":"I Faraoni","year":"2019","unstructured":"Faraoni I, Consalvo MI, Aloisio F, Graziani G, Surace CD. Cytotoxicity and differentiating effect of the poly(ADP-ribose) polymerase inhibitor Olaparib in myelodysplastic syndromes. Cancers (Basel). 2019;11(9):1373. https:\/\/doi.org\/10.3390\/cancers11091373.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"13895_CR44","doi-asserted-by":"publisher","first-page":"e74387","DOI":"10.1371\/journal.pone.0074387","volume":"8","author":"Z Hu","year":"2013","unstructured":"Hu Z, Kong F, Si M, Zhang S, Li C, Zhao X. Riccardin D exerts its antitumor activity by inducing DNA damage in PC-3 prostate cancer cells in vitro and in vivo. PLoS ONE. 2013;8(9):e74387. https:\/\/doi.org\/10.1371\/journal.pone.0074387.","journal-title":"PLoS ONE"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13895-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13895-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13895-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T20:12:28Z","timestamp":1742587948000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13895-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13895"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13895-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"assertion":[{"value":"7 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the Animal Care and Experimentation Committee, Gunma University, Showa Campus, Japan, and were conducted according to the guidelines of this committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"521"}}